Should deuterated coxitinib be taken long-term?

Deuterated colexitinib has significant efficacy in improving symptoms of psoriasis. According to multiple clinical studies, the drug can quickly and effectively improve skin lesions. Specifically, in a pivotal study, up to 68.8%of patients who received deuterated colexitinib achieved PASI after 16 weeks 75 (Psoriasis lesion area and severity index improved by 75%). This data speaks volumes about the drug's efficacy.

For patients with psoriasis, especially those with moderate to severe symptoms, it is very important to control and stabilize symptoms. Deuterated colexitinib has shown stable efficacy in long-term treatment. Research data shows that patients who continue to receive the drug have further improved response rates to PASI 75 and PASI 90 over a longer period of time (such as 52 weeks), which shows that the drug can maintain good efficacy for a long time.

Although drugs have significant efficacy, safety is equally important. Deuterated colexitinib demonstrated good safety and tolerability in clinical trials. This means that during long-term use, patients can take this drug relatively safely, and most adverse reactions are mild and controllable.

Whether long-term use of deuterated colexitinib is needed should first be decided based on the patient's specific condition and the doctor's advice. Long-term use may be beneficial for patients with moderate to severe psoriasis who require continued symptom control.

However, long-term use does not mean that treatment options are set in stone. Patients should receive regular evaluations from their doctors so that drug dosage or treatment plans can be adjusted in a timely manner according to changes in condition. Although the drug is relatively safe, you still need to pay close attention to possible adverse reactions during long-term use and report them to your doctor in a timely manner.